Enhancing Oncology Clinical Trials Through The Use Of Digital Technologies

Webcasts

Wed, Aug 17, 2022 2:00 PM EDT Recent advances in both oncology drug development and novel digital technologies provide a ripe opportunity to enhance the clinical trial process. Join Colin Weller and Musaddiq Khan from Medable as they discuss the key considerations around these innovations.

Register Free: https://www.biopharminternational.com/bp_w/enhancing-oncology

Event Overview:

Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. In this webinar, VP of Digital Trial Solutions Musaddiq Khan, VP of Product Strategy Colin Weller and Cancer Survivor Lindsey Matt will discuss how Medable is supporting a patient-first approach in complex Oncology clinical trials. Specifically, they will discuss:

  • What advances in oncology drug development mean for DCT and hybrid solutions
  • Patient-first ePRO deployment for Oncology studies
  • The evolving landscape of regulations in the DCT space
  • How to consider the patient perspective for novel solutions
  • How innovative data solutions such as tokenization can enhance insights



Key Learning Objectives:

  • How advancements such as personalized medicine require flexibility and accessibility for patients
  • How ePROs can be used in a patient-friendly way to capture data remotely and improve safety
  • The evolving regulatory perspective towards digital patient tools
  • Operational considerations to maximize patient experience, engagement, and choice within Oncology clinical trials
  • How technology can support greater insight for real time remote patient management as well as long term patient follow up



Who Should Attend:
Segment: Large Pharma, Mid-Market Biotech, CROs

Musaddiq Khan
VP, DCT Solutions
Medable

Musaddiq, or “Muz,” has been involved in clinical research for over 17 years. Most recently, he was Director of Clinical Program Operations in the Exploratory Medicine & Pharmacology group at Eli Lilly, where he led the operational delivery of the first-in-human study on Lilly’s Covid-19 antibody program. Throughout his career, Muz has held various clinical operations roles in pharma, including PAREXEL, Roche, and AstraZeneca. Muz completed his executive MBA from the University of Cambridge with a dissertation on “Developing a Digital Health Strategy for Early Clinical Development.”

Colin Weller
VP, Partner Technologies
Medable

Colin has worked in the drug development industry for more than 20 years, having spent large portions of time with Big Pharma and biotech companies such as Pfizer, Amgen, and AstraZeneca. In that time, Colin has worked across the value chain of clin ops and dev ops roles, including program management, study management, site management, and data management, as well as across a number of TAs, and has overseen the development and delivery of a number of large-scale drug development programs. Prior to joining the Product Strategy group at Medable, Colin spent the past three years building and leading a Product Management group within the Oncology Digital Health group at AstraZeneca, focusing on the development and deployment of SaMD Digital Patient Solutions and Digital Therapeutics.

Dr. Lindsey Matt
Clinical Quality Supervisor
Lyra Health

Dr. Lindsey Matt is a young adult cancer patient, clinical trial participant, clinical psychologist, wife, and mother of the happiest ten month old. She was diagnosed with Stage III colon cancer at the age of thirty-one in the midst of completing her clinical training, planning her wedding, and discussing the possibility of a family with her partner. She has since become passionate about advocating for the mental health of young adult cancer patients and survivors.

Register Free: https://www.biopharminternational.com/bp_w/enhancing-oncology